NuVasive Reports Second Quarter 2012 Financial Results
(firmenpresse) - SAN DIEGO, CA -- (Marketwire) -- 07/25/12 -- NuVasive, Inc. (NASDAQ: NUVA)
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today financial results for the quarter ended June 30, 2012.
Alex Lukianov, Chairman and Chief Executive Officer, said, "Our financial performance in the second quarter and first half of 2012 attests to excellent execution of our market-share taking strategy, and gives us confidence to raise our full year revenue and profitability guidance. We made strong improvements in profitability and will continue to balance the necessary investments into NuVasive's differentiation and share taking strategy. Looking forward, we expect our top line to grow in conjunction with an improving profitability profile and continual improvements in free cash flow. We are laying the groundwork today to become the #3 spine company in the world."
NuVasive reported second quarter 2012 revenue of $154.4 million, a 16.1% increase over the $133.0 million for the second quarter 2011 and a 1.8% increase over the $151.7 million reported for the first quarter 2012.
Gross profit for the second quarter 2012 was $117.9 million and gross margin was 76.3%, compared to a gross profit of $107.5 million and a gross margin of 80.8% for the second quarter 2011. For the first quarter 2012, gross profit was $114.8 million and gross margin was 75.7%.
Total operating expenses for the second quarter 2012 were $104.9 million compared to $96.0 million in the second quarter 2011 and $107.5 million in the first quarter 2012. The higher operating expenses in the second quarter 2012 compared to the prior year resulted primarily from additional costs associated with higher revenue and infrastructure expansion.
On a GAAP basis, the Company reported net income of $2.9 million, or $0.06 per share, for the second quarter 2012.
On a Non-GAAP basis, the Company reported net income of $12.0 million, or $0.27 per share, for the second quarter 2012. The Non-GAAP earnings per share calculation for the second quarter excludes, (i) non-cash stock-based compensation of $8.3 million; (ii) certain intellectual property litigation expenses of $0.3 million; (iii) amortization of intangible assets of $2.9 million; (iv) acquisition related items of $0.6 million; and (v) non-cash interest expense on convertible notes of $3.1 million.
Cash, cash equivalents and short and long-term marketable securities were $265.5 million at June 30, 2012.
Updated 2012 Full Year Financial Guidance
Revenue of approximately $625 million; up from previous guidance of approximately $615 million
GAAP EPS of approximately $0.16; up from previous guidance of approximately $0.09
Non-GAAP EPS of approximately $0.97; up from previous guidance of approximately $0.93
Non-GAAP Operating Margin of approximately 14.5%; up from previous guidance of approximately 14.0%
GAAP effective tax rate of approximately 55%; down from previous guidance of approximately 60%
Non-GAAP effective tax rate of approximately 40% remains unchanged
Reconciliation of Non-GAAP Information
Management uses certain Non-GAAP financial measures such as Non-GAAP operating margin and Non-GAAP earnings per share, which exclude such items as non-cash stock-based compensation, certain intellectual property litigation expenses, amortization of intangible assets, acquisition related items, and non-cash interest expense on convertible notes. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the Non-GAAP financial measures provided in this earnings release excluding these costs and uses these Non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these Non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These Non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from Non-GAAP measures used by other companies. Set forth below are reconciliations of the Non-GAAP financial measures to the comparable GAAP financial measure.
Conference Call
NuVasive will hold a conference call today at 5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at .
After the live webcast, the call will remain available on NuVasive's website, , through August 26, 2012. In addition, a telephonic replay of the call will be available until August 8, 2012. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use pin number 394522.
About NuVasive
NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $7.6 billion global spine market.
NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With over 75 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive's revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at . NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
NuVasive, Inc.
858-909-3394
858-638-5511
The Ruth Group
646-536-7030
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.07.2012 - 14:30 Uhr
Sprache: Deutsch
News-ID 1136553
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN DIEGO, CA
Phone:
Kategorie:
Surgery & Treatments
Anmerkungen:
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NuVasive Reports Second Quarter 2012 Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
NuVasive, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
